MUCORMYCOSIS DURING DEFEROXAMINE THERAPY IS A SIDEROPHORE-MEDIATED INFECTION - INVITRO AND INVIVO ANIMAL STUDIES

This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treat ed with deferoxamine (DFO). This drug aggravates mucormycosis, which w e experimentally induced in guinea pigs and which lead to a shortened animal survival (P less-than-or-equal-to 0.01 ). The drug's effect on Rhizopus is not mediated through the polymorphonuclear cells. Fe.DFO, the iron chelate of DFO, abolishes the fungistatic effect of serum on Rhizopus and increases the in vitro growth of the fungus (P less-than- or-equal-to 0.0001). This effect is present at Fe.DFO concentrations g reater-than-or-equal-to 0.01 muM, at which fungal uptake of radioiron from Fe-55.DFO is observed. A 1,000-fold higher concentration of iron citrate is required to achieve a similar rate of radioiron uptake and of in vitro growth stimulation as observed with Fe.DFO. These in vitro effects of Fe.DFO (1 muM) in serum on radioiron uptake and on growth stimulation are more striking for Rhizopus than for Aspergillus fumiga tus and are practically absent for Candida albicans. For these three f ungal species, the rates of radioiron uptake from Fe-55.DFO and of gro wth stimulation in the presence of Fe.DFO in serum are directly relate d (r = 0.886). These results underscore the major role of Fe.DFO in th e pathogenesis of DFO-related mucormycosis. Pharmacokinetic changes in uremia lead to a prolonged accumulation of Fe.DFO after DFO administr ation, which helps explain the increased sensitivity of dialysis patie nts to DFO-related mucormycosis.